Inactivated Poliovirus Vaccine (IPV) With or Without dmLT Challenge Study in Healthy Adults

Condition:   Polio Interventions:   Biological: IMOVAX Inactivated Poliomyelitis Vaccine (IPV);   Biological: dmLT (adjuvant);   Biological: Bivalent oral polio vaccine (bOPV) Sponsor:   PATH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

[Premium Times] Borno State Government on Friday said it has vaccinated more than 2.1 million children against polio in the just concluded Immunisation Plus Day exercise in the state.
Source: AllAfrica News: Polio - Category: Infectious Diseases Source Type: news
Poliomyelitis is a motor neuron disease of the anterior horn of the spinal cord. It leads to asymmetrical flaccid paralysis and muscle atrophy that reduces the patient's stability and mobility and alters the gait pattern, predisposing to falls. Until the massive clinical application of vaccines, it was quite prevalent in some countries in the 50s and, the people who suffered the epidemic during childhood is nowadays more than 65 years old, constituting a risk groups for traumatological pathology.
Source: Injury - Category: Orthopaedics Authors: Source Type: research
By Casey Bishopp, Communications officer, IntraHealth International ; Sabra Farquharson, Business development officer, IntraHealth InternationalFebruary 18, 2020We’re celebrating the legacies of ten African Americans in public health this month—shining a light on the invaluable contributions made by these scholars and health workers. According to themost recent report form the Health Resources and Services Administration, African Americans make up 11.6% of the US health workforce, and throughout American history have made invaluable contributions to greater public health in fields s...
Source: IntraHealth International - Category: International Medicine & Public Health Authors: Source Type: news
AbstractNearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live polioviruses continue to circulate with all three serotypes posing challenges for the polio endgame. We updated a global differential equation ‐based poliovirus transmission and stochastic risk model to include programmatic and epidemiological experience through January 2020. We used the model to explore the likely dynamics of poliovirus transmission for 2019–2023, which coincides with a new Global Polio Eradication Initiative Strategi c Plan. The model stratifies the global population into 72 blocks, each containi...
Source: Risk Analysis - Category: International Medicine & Public Health Authors: Tags: Original Research Article Source Type: research
The University of Pittsburgh ’s Center for Vaccine Research could have a specimen from the deadly SARS-CoV-2 coronavirus within the week in an effort by the world-renowned research institution to help create a vaccine. Pitt, where Dr. Jonas Salk created the polio vaccine, is one of the country’s leading biomedical research centers. The Center for Vaccine Research on the Pitt campus is designed to safely and efficiently handle some of the world’s most dangerous infectious diseases. It’s the…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
[WHO] Republic of Congo steps up polio vaccination in border region
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Condition:   Polio Interventions:   Biological: sIPV;   Biological: Commercialized sIPV;   Biological: Commercialized IPV Sponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Minhai Biotechnology Co., Ltd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Polio Intervention:   Biological: sIPV Sponsor:   Jiangsu Province Centers for Disease Control and Prevention Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Polio Interventions:   Biological: sIPV;   Biological: Commercialized sIPV;   Biological: Commercialized IPV Sponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Minhai Biotechnology Co., Ltd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Polio | Polio Vaccine | Research | Study | Vaccines